B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma

Yuanzhou Wu¹, Jianmin Luo¹, Hui Li¹, Yang Huang¹, Yaru Zhu², Qunqing Chen¹

¹Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China; ²Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Contributions: (I) Conception and design: Q Chen; (II) Administrative support: Q Chen; (III) Provision of study materials or patients: Y Wu; (IV) Collection and assembly of data: Y Wu, J Luo; (V) Data analysis and interpretation: J Luo, H Li, Y Huang, Y Zhu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Qunqing Chen, MD, PhD. Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, 253 Gongye Road, Guangzhou 510282, China. Email: chenqqg1985@sina.com.

Background: Lung adenocarcinoma (LUAD) is the most common malignant cancer in humans and because of low long-term survival rates, exploration of the molecular mechanisms underlying its progression, as well as novel prognostic predictors, is urgently needed. B3GNT3, a type II transmembrane protein located in the Golgi apparatus, is essential for forming extended core 1 oligosaccharides and is reportedly involved in malignant transformation.

Methods: The Cancer Genome Atlas (TCGA) and GSE68465 were used to analyze the expression of B3GNT3 in LUAD and normal tissues and overall survival. Real time quantitative polymerase chain reaction (qPCR) and western blot were conducted to measure the mRNA and protein levels of B3GNT3, respectively. Functional enrichment of differentially expressed genes was explored using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. We performed univariate and multivariate Cox regression analyses and a meta-analysis to reveal an independent factor for LUAD. We evaluated the correlation between immune infiltration levels and cumulative survival in the TIMER database. The correlation between B3GNT3 and immune cell infiltration was assessed via Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT). The association of DNA methylation of B3GNT3 and prognosis was determined. A nomogram that incorporated expression and clinical features was additionally built for prognostic prediction. Cell proliferation, cloning, and invasion were conducted to validate the roles of B3GNT3 in LUAD.

Results: B3GNT3 was more highly expressed in LUAD tissues than in normal lung tissues, consistent with the mRNA and protein levels in LUAD cells. B3GNT3 was an independent factor for LUAD. Moreover, the levels of B3GNT3 were related to immune cell infiltration in LUAD microenvironments. DNA methylation of B3GNT3 correlated with the mRNA of B3GNT and overall survival of LUAD patients. The expression of B3GNT3 was highly valuable for the prediction of diagnosis. Knockdown of B3GNT3 inhibited LUAD cell viability and cloning ability, and hindered invasion.

Conclusions: B3GNT3 was highly associated with immune cell infiltration, acting as an important biomarker for the prognosis and diagnosis of LUAD.

Keywords: B3GNT3; biomarker; immune cell infiltration; lung adenocarcinoma (LUAD); prognosis

Submitted Jan 11, 2022. Accepted for publication Mar 01, 2022.
doi: 10.21037/atm-22-493

View this article at: https://dx.doi.org/10.21037/atm-22-493
**Introduction**

Lung cancer is the most prevalent cancer with high mortality, accounting for more than 18 million new cancer cases and 9 million cancer-related deaths worldwide (1). Lung adenocarcinoma (LUAD) is the primary subtype of lung cancer, accounting for approximately 50% of all lung cancer patients (2). Over the past decade, integrated treatments such as surgical resection, chemotherapy, radiotherapy, and molecular-targeted therapy have been provided for LUAD patients (3-5), but overall survival (OS) rates have not significantly improved. Targeted therapies using tyrosine kinase inhibitors (TKI) such as gefitinib, erlotinib, and crizotinib have revolutionized the treatment of the adenocarcinoma subtype (6-9). However, efficacy is limited by acquisition of mutations, resulting in cancer progression for the majority of LUAD patients. It is vital to understand the mechanisms underlying LUAD progression and explore potential biomarkers.

B3GNT3, Beta-1,3-N-acetylglucosaminyltransferase 3, is a type II transmembrane protein located in the Golgi apparatus and is essential for forming extended core 1 oligosaccharides (10,11). Numerous studies have reported the involvement of B3GNT3 in malignant transformation and B3GNT3 expression is strongly correlated with PD-L1 levels and EGFR mutation status (12-19). It has been indicated that B3GNT3 expression is strongly correlated with PD-L1 levels and EGFR mutation status. High expression of B3GNT3 is associated with advanced histologic grade and poorer OS. However, in neuroblastoma B3GNT3 expression inhibits cell migration and invasion and predicts favorable outcomes (14). It has been determined that the tumor-infiltrating immune cells are correlated with the development, progression and prognosis of LUAD (20). Moreover, DNA methylation is associated with the expression of gene and reduces tumor immunity and the prognosis of patients with LUAD (21). However, the methylation and B3GNT3 remains unclear. Therefore, the role of B3GNT3 in LUAD is controversial.

Our study detected that B3GNT3 was more highly expressed in tumor tissues than in normal tissues and more in LUAD cell lines than in human bronchial epithelial cells. B3GNT3 was also related to poorer OS for LUAD patients. Furthermore, B3GNT3 was identified as an independent prognostic factor. Strikingly, B3GNT3 was involved in immune cell infiltration and might correlate with VTCN1, VSIR, CTLA-4, and CD276 for LUAD immunotherapy. Furthermore, the results suggested a strong correlation of B3GNT3 DNA methylation with mRNA levels and survival. Therefore, we identified B3GNT3 as an important biomarker and validated the prognostic and predictive values for LUAD. We present the following article in accordance with the MDAR reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-493/rc).

**Methods**

**Data collection and bioinformatic analysis**

The RNA expression profile and corresponding clinical characteristics were downloaded from The Cancer Genome Atlas (TCGA). GSE68465 (22) from the GEO database had 442 lung adenocarcinomas enrolled for mRNA. To detect the protein levels of B3GNT3, the Human Protein Atlas (HPA) database was accessed for the immunohistochemistry results for tumors and normal tissues. To analyze genomic alternations, we measured the alteration rates based on the cBioPortal tool. Furthermore, we examined the association between B3GNT3 expression and DNA methylation using the MEXPRESS tool (http://mexpress.be/) (23). Data on gene methylation were downloaded from the UCSC Xena browser (https://xena.ucsc.edu/). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

**Cell culture**

LUAD cell lines (A549 and PC9) and human bronchial epithelial cell line BEAS-2B were purchased from the American Type Culture Collection. Cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum (Gibco, CA, USA) at 37 °C in a humidified incubator with 5% CO₂ at 37 °C.

**RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

Total RNA was extracted from cells by TRIzol reagent (Invitrogen, NY, USA). cDNAs were generated from RNA via reverse transcription using PrimeScript RT Master Mix (TIANGEN, Beijing, China). The primers for GAPDH were as follows: Forward 5’-GTCTCCTCTCTGAC TTCAAGGCCG-3’ and Reverse 5’-ACCACCTGGTTG CTGTAGCACA-3’. The primers for B3GNT3 were Forward 5’-TATGTGTCTGGAGCTTGAGG-3’, Reverse 5’-AAGGATGTGAGGTGTTCCG-3’. qRT-PCR was performed using the SYBR Premix Ex
Taq reaction system according to the manufacturer’s instructions. The levels of mRNA were measured by calculating $2^{-\Delta\Delta CT}$.

**Western blot assay**

Total proteins were extracted from cells, and the same amounts were loaded on the 12% SDS-PAGE gels and then blotted onto polyvinylidene fluoride membranes. After blocking with non-fat milk for 1.5 h, the blots were incubated with the primary antibodies for B3GNT3 (NBP1-32539; Novus Biologicals, USA) and GAPDH (ab8245, Abcam, UK) at 4 °C overnight. Subsequently, the membranes were incubated with secondary antibodies for 1 h.

**Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses and protein-protein interaction (PPI)**

Differentially expressed genes (DEGs) were identified by the criteria of adjusted P value <0.05 and log 2-fold change (FC) >0.5. We performed GO enrichment analysis comprising biological process (BP), cellular components (CC), and molecular function (MF), and KEGG for DEGs to explore the utilities of the biological functions using the R package “clusterProfiler” (24,25). Gene expression profiles of LUAD patients were divided into high and low groups according to the median value of expression of B3GNT3. Gene set enrichment analysis (GSEA) was utilized to detect possible mechanisms underlying the effect of B3GNT3 expression on LUAD prognosis. In addition, gene set variation analysis (GSVA) was used to detect the pathways most associated with B3GNT3. A PPI network helped us explore novel molecules with B3GNT3. The STRING (https://string-db.org/) database is a tool for searching the interactions among different proteins. Significantly associated genes with weight value >0.8 were collected to construct the PPI network.

**Identification of an independent factor for LUAD patients**

Univariate and multivariate regression analyses, and a meta-analysis using the TCGA and GSE68465 for the hazard ratio (HR) in LUAD were performed to determine an independent prognostic factor.

**Correlation between gene expression and immune cell infiltration**

The tool CIBERSORT (Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts) was applied to investigate the correlation between B3GNT3 and 22 immune cells. We assessed the correlation between expression of B3GNT3, copy number alteration (CNA), and tumor-infiltrating immune cells by TIMER (https://cistrome.shinyapps.io/timer/), which included different types of cancer samples accessible in the TCGA. We examined the association between B3GNT3 and key checkpoints for its possible use in immune therapy.

**Construction and evaluation of a predictive nomogram**

All independent prognostic parameters and relevant clinical parameters were included in the construction of a prognostic nomogram via a stepwise Cox regression model to predict 1-, 3-, and 5-year overall survival of patients in the TCGA dataset. A nomogram was established via the RMS package in R (26-28).

**Cell transfection**

RNA interference of B3GNT3 was performed using small interfering RNA (siRNA). Cells were transfected with non-specific scramble (scr) siRNA as a control and siB3GNT3 using Lipofectamine 3000 (Invitrogen, CA, USA). The siRNAs used were: siB3GNT3 sense 5’-CAGACAACAUGGUCUUCUAtt-3’ and antisense 5’-TAGAAGACCATGTTGTCTGtg-3’.

**Cell proliferation, cloning, and invasion**

Proliferative ability was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer’s instructions. A microplate reader was used to examine the absorbance values at 490 nm. One thousand cells per well were seeded in 6-well plates and cultured for 2 weeks. Colonies were immobilized with 10% formaldehyde for 5 min and then stained with 1.0% crystal violet for 30 s. For the invasion assay, after 48 h of incubation, cells in the lower chamber were stained with 0.1% crystal violet and counted under a microscope with 6 different fields per filter.
Statistical analysis

All the values are presented as mean ± standard deviation (SD). A t-test and one-way analysis of variance were applied to assess the differences between groups. P<0.05 was considered a significant difference.

Results

Levels of B3GNT3 mRNA in LUAD

Gene expression analyses using the UCSC Xena database indicated that B3GNT3 expression was significantly higher in bladder urothelial carcinoma (BLCA), cholangiocarcinoma (CHOL), kidney renal papillary (KIRP), liver hepatocellular carcinoma (LIHC), LUAD, lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC), but the levels of B3GNT3 mRNA were much lower in breast invasive carcinoma (BRCA), kidney chromophobe (KICH), and prostate adenocarcinoma (PRAD), compared with corresponding normal tissues (Figure 1A). Moreover, based on both the TCGA-LUAD database and GSE68465 dataset, B3GNT3 was overexpressed in LUAD tissues (Figure 1B). In addition, the expression of B3GNT3 was much higher in A549 and PC9 cells than in BEAS-2B cells (Figure 1C). Moreover, B3GNT3 protein was lower in BEAS-2B cells than in A549 and PC9 cells (Figure 1D). Furthermore, the HPA determined that B3GNT3 protein levels in LUAD tissues were much higher than in normal lung tissues (Figure 1E). The B3GNT3 protein might be distributed in the cytoplasm and membranes. Thus, all data indicated high expression of B3GNT3 might be associated with LUAD.

Prognostic value of B3GNT3 in LUAD

The characteristics of LUAD patients with B3GNT3 levels from the TCGA are presented in Table 1. In the TCGA-LUAD database, among 4 clinicopathological features, high expression of B3GNT3 was associated with pathological T and pathological N categories, but not with age or sex. Moreover, a consistent finding was determined from the GSE68465 dataset (Figure 2A). To further explore the prognosis of B3GNT3, a total of 332 LUAD patients from the TCGA database were divided into two groups according to the expression of B3GNT3. The Kaplan-Meier curve suggested that patients with high expression suffered worse OS rates than patients with low expression, which was similar to the results from GSE68465 (Figure 2B). To detect the mutation of B3GNT3, the rates of genetic alteration were 1.4% in patients from 7 different studies (Figure 2C). Therefore, the evidence suggested high levels of B3GNT3 are related to poor prognosis.

Functional enrichment of DEGs based on B3GNT3

To identify the DEGs based on the expression of B3GNT3, DEGs were obtained by RNA-seq from the GSE68465 dataset. A total of 165 DEGs (106 upregulated and 59 downregulated genes) were identified (Figure 3A, https://cdn.amegroups.cn/static/public/atm-22-493-1.xls). The top 100 DEGs are shown in Figure 3B. To detect the functional enrichment of the DEGs, we used GO annotation, including BP, CC, and MF. Enriched BPs were O-glycan processing, epidermis development and protein O-linked glycosylation. In terms of CC, the DEGs were enriched with laminin complex, Golgi lumen, and intermediate filament, and for MF, they were enriched in the structural constituents of the cytoskeleton, aromatase activity and serine-type endopeptidase inhibitor activity. KEGG analysis indicated that the DEGs were most enriched in the interleukin-17 signaling pathway, amoebiasis, and retinol metabolism (Figure 3C). Furthermore, GSEA demonstrated that the DEGs were associated with cell cycle, P53 signaling pathway, and valine leucine and isoleucine degradation (Figure 3D). In addition, GSVA suggested that these DEGs highly affected the development of LUAD (Figure 3E). Our data revealed that DEGs could be involved in the development of LUAD.

Identification of key candidate genes

A protein-protein interaction was constructed to analyze the possible targets of B3GNT. In total, 67 genes were identified as key genes that were highly associated with B3GNT3 (Figure 4). The genes that were significantly correlated with B3GNT3 were GJB3, ITGB4, PTPRH, KRT19 and LAMC2.

An independent factor for the prognosis of LUAD

To determine whether B3GNT3 was an independent factor, univariate Cox analysis was performed. Our data showed that pathological T and N categories, and B3GNT3 were significantly associated with survival in the TCGA. In the
Figure 1 High expression of B3GNT3 is related to LUAD. Expression levels of B3GNT3 in different types of cancers compared with normal tissues from (A) the UCSC Xena database and (B) TCGA and GSE68465. (C) qPCR shows the mRNA levels of B3GNT3 in cell lines and (D) western blot shows the protein levels of B3GNT3 in cell lines. (E) Protein levels of B3GNT3 by immunohistochemical staining analysis based on the Human Protein Atlas database (10×). **, P<0.01; ****, P<0.0001, ns, not significant. TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, squamous cell cancer in head and neck; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; qPCR, quantitative polymerase chain reaction.
Table 1 Characteristics of patients with lung adenocarcinoma and B3GNT3 expression levels from The Cancer Genome Atlas

<table>
<thead>
<tr>
<th>Patients</th>
<th>High expression (N=118)</th>
<th>Low expression (N=119)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td>0.842</td>
</tr>
<tr>
<td>Female</td>
<td>54 (45.8)</td>
<td>57 (47.9)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>64 (54.2)</td>
<td>62 (52.1)</td>
<td></td>
</tr>
<tr>
<td>Age (years), n (%)</td>
<td></td>
<td></td>
<td>0.851</td>
</tr>
<tr>
<td>&lt;65</td>
<td>52 (44.1)</td>
<td>50 (42.0)</td>
<td></td>
</tr>
<tr>
<td>&gt;65</td>
<td>66 (55.9)</td>
<td>69 (58.0)</td>
<td></td>
</tr>
<tr>
<td>Stage, n (%)</td>
<td></td>
<td></td>
<td>0.0066</td>
</tr>
<tr>
<td>I</td>
<td>48 (40.7)</td>
<td>68 (57.1)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>27 (22.9)</td>
<td>30 (25.2)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>30 (25.4)</td>
<td>16 (13.4)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>13 (11.0)</td>
<td>5 (4.2)</td>
<td></td>
</tr>
<tr>
<td>T, n (%)</td>
<td></td>
<td></td>
<td>0.258</td>
</tr>
<tr>
<td>T1</td>
<td>32 (27.1)</td>
<td>39 (32.8)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>65 (55.1)</td>
<td>68 (57.1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>14 (11.9)</td>
<td>6 (5.0)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>7 (5.9)</td>
<td>6 (5.0)</td>
<td></td>
</tr>
<tr>
<td>N, n (%)</td>
<td></td>
<td></td>
<td>0.124</td>
</tr>
<tr>
<td>0</td>
<td>64 (54.2)</td>
<td>81 (68.1)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>29 (24.6)</td>
<td>23 (19.3)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>24 (20.3)</td>
<td>15 (12.6)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>M, n (%)</td>
<td></td>
<td></td>
<td>0.215</td>
</tr>
<tr>
<td>0</td>
<td>105 (89.0)</td>
<td>114 (95.8)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>10 (8.5)</td>
<td>3 (2.5)</td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>1b</td>
<td>2 (1.7)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Cigarettes per day</td>
<td></td>
<td></td>
<td>0.624</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.38 (1.52)</td>
<td>2.28 (1.50)</td>
<td></td>
</tr>
<tr>
<td>Median (min, max)</td>
<td>2.19 (0.00822, 8.44)</td>
<td>2.05 (0.110, 8.05)</td>
<td></td>
</tr>
<tr>
<td>Status, n (%)</td>
<td></td>
<td></td>
<td>0.935</td>
</tr>
<tr>
<td>Alive</td>
<td>73 (61.9)</td>
<td>72 (60.5)</td>
<td></td>
</tr>
<tr>
<td>Dead</td>
<td>45 (38.1)</td>
<td>47 (39.5)</td>
<td></td>
</tr>
</tbody>
</table>

T, tumor; N, node; M, metastasis; SD, standard deviation.
Figure 2 Association of B3GNT3 with the prognosis of LUAD patients. (A) Expression of B3GNT3 according to sex, age, T category and N category in the TCGA and GSE68465; (B) Kaplan-Meier curves of overall survival based on low and high B3GNT3 expression in LUAD patients from the TCGA; (C) genetic alterations of B3GNT3 investigated in the databases. *, P<0.05. LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.
Figure 3 Involvement of B3GNT3 in the pathways of cancer development. (A) Volcano plot visualizing DEGs between high and low expression groups for B3GNT3 in the TCGA. The color from blue to red represents the progression from low expression to high expression. (B) Heatmaps of DEGs based on the expression of B3GNT3. (C) Results of analyses of BP, CC and MF terms. (D) GSEA showing activated and inhibited signaling pathways of B3GNT3 and (E) GSVA showing enriched signaling pathways of B3GNT3. DEGs, differentially expressed genes; TCGA, The Cancer Genome Atlas; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; GSVA, gene set variation analysis.
GSE68465 cohort, sex, pathological T and N categories, and B3GNT3 were highly related to LUAD survival rates (Figure 5A). However, the multivariate Cox regression model indicated that T and N categories were significantly associated with prognosis. T and N categories, and B3GNT3 highly correlated with the survival of LUAD patients (Figure 5B). Additionally, from our meta-analysis the HR was 1.19 (confidence interval: 1.08–1.32, $I^2=0$) (Figure 5C). Therefore, B3GNT3 was likely to be an independent prognosticator for LUAD.

**Correlation between the expression of B3GNT3 and immune cell infiltration and checkpoints**

To further determine the role of B3GNT3 in the tumor microenvironment (TME), we explored the association between B3GNT3 and 22 immune cells. Notably, in the TCGA database, plasma cells and resting CD4 memory T cells were enriched in the samples of the low-B3GNT3 group, whereas M0 macrophages were enriched in the samples of the high-B3GNT3 group (Figure 6A). In the GSE68465 dataset, a significant association was found between the samples in the low-B3GNT3 group and gamma-delta T cells and resting dendritic cells. The samples in the high-B3GNT3 group significantly correlated with resting natural killer cells, M0 macrophages, activated dendritic cells, and neutrophils (Figure 6B). Additionally, our findings indicated that B3GNT3 were associated with tumor purity, B cells, and neutrophils (Figure 6C). B cells and dendritic cells were associated with survival of LUAD (Figure 6D). We also determined the association of B3GNT3 and immune checkpoints by referring to the TCGA database. The levels of B3GNT3 might correlate with VTCN1 (B7-H4), VSIR (B7-H5), CTLA-4, and...
Figure 5 Validation of B3GNT3 as an independent factor for LUAD in the TCGA and GSE68465. (A) Univariate Cox analysis to evaluate the prognostic value of common clinical parameters and B3GNT3; (B) multivariate Cox analysis to evaluate the prognostic value of common clinical parameters and B3GNT3; (C) Forest plot of HRs of B3GNT3 expression and the prognosis of LUAD patients. TE: logHR; seTE: SE (logHR). LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; HRs, hazard ratios.

CD276 (B7-H3) (Figure 6E). Furthermore, we explored the effect of somatic CNA on the level of infiltration of different immune cells. The arm-level deletion of B3GNT3 CNA was significantly associated with B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells. Moreover, arm-level deletion of B3GNT3 CNA greatly affected macrophages and dendritic cells (Figure 6F). Therefore, our results suggested that B3GNT3 correlated with immune cell infiltration and immune checkpoints.

Association between DNA methylation of B3GNT3 and prognosis of LUAD

The association between B3GNT3 expression and DNA methylation was shown in Figure 7A. The association between DNA methylation and the expression of mRNA in LUAD was analyzed \( (r=-0.116, P=0.0133) \), indicating that B3GNT3 expression negatively correlated with the DNA methylation level (Figure 7B). A significant association between 10 methylation sites and the level of B3GNT3
Figure 6 Association of B3GNT3 with immune cell infiltration and checkpoints in LUAD. Comparisons of 22 infiltrating immune cells in high- and low-risk groups in (A) the TCGA and (B) GSE68465. (C) Relationship between B3GNT3 and the level of infiltration of 6 types of immune cells. (D) Relationship between B cells, CD4+ and CD8+ T cells, dendritic cells, macrophages, neutrophils and cumulative survival rate in LUAD. (E) Correlation between B3GNT3 and the immune checkpoints in the TCGA-LUAD dataset. (F) Effect of genetic alterations of B3GNT3 on immune cell infiltration. *, P<0.05; **, P<0.01; ***, P<0.001. LUAD, lung adenocarcinoma.
mRNA was found (Figure 7C). Furthermore, two CpG island methylation levels (cg01289421 and cg10831285) of B3GNT3 significantly influenced the OS rate of LUAD patients (Figure 8).

**Nomogram construction**

To identify an individual’s risk, a nomogram was created based on the TCGA and GSE68465 dataset to predict the 1-, 3-, and 5-year survival rates. The nomogram contained 7 prognostic factors, including sex, age, pathological T and N categories B3GNT3 (Figure 9). After a comprehensive assessment of prognostic value, the risk model was considered as a biomarker, exerting predictive value for LUAD patients.

**Effect of knockdown of B3GNT3 on LUAD cell proliferation, cloning, and invasive ability**

To understand the functions of B3GNT3, we transfected siRNA into LUAD cells (A549 and PC9) to knockdown the mRNA levels of B3GNT3. It was showed that the mRNA of B3GNT3 was highly downregulated by as much as 67% in A549 and 70% in PC9 (Figure 10A). MTT assay measured cell viability after suppression of B3GNT3, revealing a significant downregulation of cell viability of A549 and PC9 cells after 72 h (Figure 10B). Meanwhile, we found the number of cell colony formation units was dramatically reduced after downregulation of B3GNT3 in A549 and PC9 cells (Figure 10C). Our transwell assays revealed that B3GNT3 knockdown significantly suppressed cell invasion in A549 and PC9 cells (Figure 10D). Therefore, LUAD cell proliferation, cloning, and invasion were significantly inhibited after downregulation of B3GNT3.

**Discussion**

Lung cancer led to more than 140,000 cancer-related deaths in the USA in 2019 (2). The emerging targeted therapy has provided the possibility of prolonging survival, but more novel therapeutic targets urgently need to be identified. B3GNT3 has been reported as an oncogene in a few cancer cases and is involved in cell proliferation and lymphocyte trafficking (12,16,18). However, there is no integrated and comprehensive study in this area, particularly regarding the methylation of B3GNT3 in LUAD patients.

In our current work, the mRNA levels of B3GNT3 were much higher in tumor tissues than in adjacent normal tissues from three different databases, which was also validated in our cell lines. The levels of B3GNT3 protein were determined using the HPA database and western blot, indicating higher expression in LUAD tissues and LUAD cells than in normal lung tissues and human bronchial epithelial cells, respectively. Consistent with our findings, B3GNT3 was revealed as a carcinogenic factor by presenting higher expression in pancreatic cancer (16), early-stage cervical cancer (15), neuroblastoma (14), and endometrial cancer tissues than in normal tissues (29). In our study, high levels of B3GNT3 were associated with poor prognosis with advanced stage and higher mortality rates, which was also indicated in previous lung cancer (19) and non-small cell lung cancer studies (12). Moreover, the genetic alteration of B3GNT3 was 1.4% in LUAD patients from several datasets, which suggests the possibility of improving the prognosis by targeting B3GNT3. To determine the possible mechanisms of B3GNT3, we conducted GESA and GSVA to analyze DEGs, which were enriched in cancer development, emphasizing the carcinogenic role of B3GNT3 and supporting our conclusions. Based on the results of our univariate analysis, multivariate Cox regression analysis, and meta-analysis from the TCGA and GSE68465, we concluded that B3GNT3 was an independent factor of the prognosis of LUAD, similar to its role in non-small cell lung cancer and early-stage cervical cancer (15). We consider that B3GNT3 was validated as an independent carcinogenic factor that significantly affects the prognosis of LUAD patients.

Increasing attention is being given to the TME, including immune cell infiltration. Our study found that M0 macrophages tend to be enriched in patients with high expression of B3GNT3 in both the TCGA-LUAD and GEO databases. Abundance of M0 macrophages has been linked to significantly poor OS rates for LUAD patients in other studies (30,31). B3GNT3 also correlated with B cells and neutrophils, which were significantly associated with LUAD survival based on our data. Our conclusions were similar to one previous study asserting that tumor-infiltrating B lymphocytes result in favorable outcomes (32). The potential mechanisms need to be investigated by subsequent fundamental research focusing on the functions of B cells in LUAD. Consistent with our research, another study demonstrated that neutrophils alter angiogenesis and increase hypoxia to maintain a deleterious TME, which indicates a novel role of neutrophils (33). Furthermore, dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer, playing an important
Figure 7 Correlation between methylation level of 13 sites and gene expression. (A) Visualization of the association between B3GNT3 expression and DNA methylation in the TCGA-LUAD cohort via the MEXPRESS tool. B3GNT3 gene together with its transcripts is indicated in the left bottom panel. (B) Correlation of B3GNT3 methylation with mRNA expression. (C) Association between different methylation sites and the expression of B3GNT3. LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.

role in tumor immunity (34). Based on these other studies, we believe that B3GNT3 might affect M0 macrophages, B cells, neutrophils, and dendritic cells, leading to a poor prognosis for LUAD.

We also explored the association between B3GNT3 and several checkpoints, including VTCN1 (B7-H4), VSIR
(B7-H5), TIGIT, PDCD1LG2 (PD-L2), PDCD1 (PD-1), LAG3, HAVCR2 (TIM-3), CTLA4, CD276 (B7-H3), and CD274 (PD-L1). Our results demonstrated that B3GNT3 highly correlated with VTCN1 (B7-H4) and CD276 (B7-H3). B7-H3 and B7-H4 were validated as inhibiting the activation and function of T cells, potently suppressing the proliferation, cytokine production, and cytotoxicity of activated T cells (35,36). Enoblituzumab, a monoclonal antibody targeting B7-H3, was the first agent to enter clinical practice, and has shown acceptable tolerability and efficacious results in combination with pembrolizumab in patients with various solid malignancies (37). Thus, the data suggest that B3GNT3 might correlate with multiple biomarkers for immunotherapy in LUAD, although further validation involving larger clinical cohorts is urgently needed.

Figure 8 Kaplan-Meier analysis of overall survival in LUAD patients stratified according to B3GNT3 methylation. LUAD, lung adenocarcinoma.

Figure 9 Nomogram to predict 1-, 3- and 5-year overall survival in the TCGA cohort and GSE68465. TCGA, The Cancer Genome Atlas.
Figure 10 Knockdown of B3GNT3 inhibited the proliferation, cloning and invasion of LUAD cells. (A) qPCR shows the relative levels of B3GNT3 after transfection of siRNA. (B) 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) analysis of the proliferation of A549 and PC9 cells after 24, 48 and 72 h. (C) Colony formation assay of the cloning ability of A549 and PC9 cells (crystal violet staining, 10×). (D) Transwell cell assays demonstrate cell invasion with crystal violet in siB3GNT3-transfected A549 and PC9 cells compared with non-specific scramble (scr) siRNA as a control group, 10×. siRNA, small interfering RNA. *, P<0.05; **, P<0.01; ***, P<0.001. LUAD, lung adenocarcinoma; qPCR, quantitative reverse transcription polymerase chain reaction.
To our knowledge, this study is the first to focus on the methylation of B3GNT3. DNA methylation is a common modification that participates in the initiation and process of LUAD. Our study found a significant association of B3GNT3 DNA methylation with mRNA expression at 10 of 13 analyzed CpG sites, and with survival at 2 of 13 sites for LUAD patients. In addition, our nomogram indicated that B3GNT3 was a predictive biomarker in LUAD. Similarly, TNFRSF9 DNA methylation acts as a novel biomarker, regulating mRNA expression (38). In the early-stage breast cancer, S100P methylation in the blood was validated to have predictive value. To validate the role of B3GNT3 in LUAD, we performed cell proliferation, cloning, and invasion studies, which supported our hypothesis. One possible mechanism is that B3GNT3 binds to miR-149-5p directly to promote the development of LUAD (19). Thus, B3GNT3 could be a prognostic and predictive biomarker for LUAD.

**Conclusions**

High expression of B3GNT3 was related to poor prognosis, acting as an independent factor for LUAD, and involved in both immune cell infiltration and several immune checkpoints. Moreover, a significant correlation of B3GNT3 DNA methylation with mRNA expression and survival was determined, showing predictive value for LUAD. Further research is needed to explore the potential mechanisms and therapeutic value of B3GNT3 in LUAD.

**Acknowledgments**

**Funding:** None.

**Footnote**

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at [https://atm.amegroups.com/article/view/10.21037/atm-22-493/rc](https://atm.amegroups.com/article/view/10.21037/atm-22-493/rc)


Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at [https://atm.amegroups.com/article/view/10.21037/atm-22-493/coif](https://atm.amegroups.com/article/view/10.21037/atm-22-493/coif)). The authors have no conflicts of interest to declare.

**References**

lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell 2001;105:957-69.


(English Language Editor: K. Brown)